Friday, March 01, 2019 8:47:17 PM
Great move in AH but closed negative.
Let's see what happens next week.
Let's see what happens next week.
Article I, Section. 10. No State shall...make any Thing but gold and silver Coin a Tender in Payment of Debts;...or Law impairing the Obligation of Contracts [ask GM bondholders!].
Recent TNXP News
- Tonix Pharmaceuticals to Participate in Two Investor Conferences in May • GlobeNewswire Inc. • 05/12/2026 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 09:17:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 09:15:25 PM
- Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights • GlobeNewswire Inc. • 05/11/2026 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 09:20:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:05:40 AM
- Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/01/2026 08:57:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:28 AM
- Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at J • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 11:11:37 AM
- Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 • GlobeNewswire Inc. • 04/23/2026 11:00:00 AM
- Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development • GlobeNewswire Inc. • 04/15/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 11:05:34 AM
- Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 • GlobeNewswire Inc. • 03/31/2026 11:00:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/30/2026 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 11:00:28 AM
- Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain • GlobeNewswire Inc. • 03/26/2026 11:00:00 AM
- Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 • GlobeNewswire Inc. • 03/23/2026 08:32:42 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/20/2026 09:12:47 PM
- Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 • GlobeNewswire Inc. • 03/18/2026 08:58:49 PM
- Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 • GlobeNewswire Inc. • 03/17/2026 08:35:00 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 10:01:04 AM
- Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights • GlobeNewswire Inc. • 03/12/2026 09:30:00 PM
